ALK Abello's Needle-Free Adrenaline Spray Gains Traction as Anaphylaxis Management Falls Short — ALK-Abelló A/S

Event summary

54% of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed, and nearly 40% do not carry one regularly (n=1,238).
EURneffy®, the only needle-free nasal adrenaline spray, was strongly and consistently preferred over AAIs by patients across four countries in a discrete choice experiment.
In a simulated-use study, participants said they would find EURneffy® significantly easier to use and would act earlier than with an AAI.
ALK presented new scientific data at the 2026 EAACI Annual Congress in Istanbul, Turkey, highlighting the potential of EURneffy® to address practical and psychological challenges in anaphylaxis management.

The big picture

ALK Abello's EURneffy® addresses a critical gap in anaphylaxis management, where adherence to adrenaline auto-injectors is notoriously low. The needle-free nasal spray offers a promising alternative, particularly for patients who avoid AAIs due to fear of needles or uncertainty during reactions. The strategic shift towards needle-free adrenaline delivery could reshape the anaphylaxis treatment landscape, potentially improving patient outcomes and reducing the burden of severe allergic reactions.

What we're watching

Market Adoption: How quickly EURneffy® can gain market share against established AAIs, particularly among adolescents and those with needle phobia.
Regulatory Approvals: Whether EURneffy® can secure additional regulatory approvals beyond the EU, UK, US, Japan, China, Australia, and Canada.
Clinical Efficacy: The pace at which real-world data confirms the efficacy and safety of EURneffy® in emergency anaphylaxis situations.